Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2010-12

AUTHORS

Milind M Javle, Rachna T Shroff, Henry Xiong, Gauri A Varadhachary, David Fogelman, Shrikanth A Reddy, Darren Davis, Yujian Zhang, Robert A Wolff, James L Abbruzzese

ABSTRACT

BACKGROUND: The phosphoinositide 3-kinase (PI3K)/Akt pathway is constitutively activated in pancreatic cancer and the mammalian target of rapamycin (mTOR) kinase is an important mediator for its signaling. Our recent in vitro studies suggest that prolonged exposure of pancreatic cancer cells to mTOR inhibitors can promote insulin receptor substrate-PI3K interactions and paradoxically increase Akt phosphorylation and cyclin D1 expression in pancreatic cancer cells (negative feedback loop). The addition of erlotinib to rapamycin can down-regulate rapamycin-stimulated Akt and results in synergistic antitumor activity with erlotinib in preclinical tumor models. METHODS: Two studies prospectively enrolled adult patients with advanced pancreatic cancer, Eastern Cooperative Oncology Group performance status 0-1, adequate hematologic, hepatic and renal parameters and measurable disease. In Study A, temsirolimus was administered intravenously at 25 mg weekly. In Study B, everolimus was administered orally at 30 mg weekly and erlotinib was administered at 150 mg daily. The primary endpoint in both studies was overall survival at 6 months. Secondary endpoints included time to progression, progression-free survival, overall survival, response rate, safety and toxicity. Pretreatment tumor biopsies were analyzed by immunofluorescence and laser scanning cytometry for the expression of pmTOR/mTOR, pAkt/Akt, pErk/Erk, pS6, p4EBP-1 and PTEN. RESULTS: Five patients enrolled in Study A; Two patients died within a month (rapid disease progression and hemorrhagic stroke, respectively). One patient developed dehydration and another developed asthenia. Sixteen patients enrolled in Study B.: 12 males, all ECOG PS = 1. Median cycles = 1 (range 1-2). Grade 4 toxicity: hyponatremia (n = 1), Grade 3: diarrhea (n = 1), cholangitis (n = 3), hyperglycemia (n = 1), fatigue (n = 1). Grade 2: pneumonia (n = 2), dehydration (n = 2), nausea (n = 2), neutropenia (n = 1), mucositis (n = 2) & rash (n = 2). Four patients were hospitalized. Progressive disease occurred in 15 and 1 was non-evaluable. Pretreatment biopsies revealed a higher pAkt/Akt ratio in tumor specimens that in nonmalignant pancreatic tissue. No such trends were noted for the other biomarkers. CONCLUSIONS: Neither study with mTOR inhibitors demonstrated objective responses or disease stability. The negative feedback loop resulting from mTOR inhibition may account for the disease progression and toxicity noted in these studies. Future strategies should aim for a broader targeting of the PI3K pathway in pancreatic cancer. TRIAL REGISTRATION: TRIAL REGISTRATION: STUDY A: NCT 0075647. STUDY B: NCT00640978. More... »

PAGES

368

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1471-2407-10-368

DOI

http://dx.doi.org/10.1186/1471-2407-10-368

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1008418244

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20630061


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Erlotinib Hydrochloride", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Everolimus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorescent Antibody Technique", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoenzyme Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppressive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phosphorylation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-akt", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinazolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, Epidermal Growth Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Signal Transduction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sirolimus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "TOR Serine-Threonine Kinases", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, UT-M D Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Javle", 
        "givenName": "Milind M", 
        "id": "sg:person.01170552013.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170552013.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, UT-M D Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shroff", 
        "givenName": "Rachna T", 
        "id": "sg:person.01120712765.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01120712765.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Cancer and Blood Disorders", 
          "id": "https://www.grid.ac/institutes/grid.477919.5", 
          "name": [
            "Center for Cancer and Blood Disorders, Dallas, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xiong", 
        "givenName": "Henry", 
        "id": "sg:person.016444546257.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016444546257.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, UT-M D Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Varadhachary", 
        "givenName": "Gauri A", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, UT-M D Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fogelman", 
        "givenName": "David", 
        "id": "sg:person.01137701711.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137701711.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, UT-M D Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reddy", 
        "givenName": "Shrikanth A", 
        "id": "sg:person.012547340642.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012547340642.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Apocell Inc, 2575 West Bellfort, Suite 190, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Davis", 
        "givenName": "Darren", 
        "id": "sg:person.01143530612.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01143530612.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Apocell Inc, 2575 West Bellfort, Suite 190, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Yujian", 
        "id": "sg:person.01240504261.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240504261.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, UT-M D Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wolff", 
        "givenName": "Robert A", 
        "id": "sg:person.01133335751.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133335751.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, UT-M D Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abbruzzese", 
        "givenName": "James L", 
        "id": "sg:person.0645263515.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645263515.62"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1097/01.cco.0000143964.74936.d1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003424823"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.cco.0000143964.74936.d1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003424823"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.cco.0000143964.74936.d1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003424823"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-06-0166", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004420604"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.07.9525", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005176755"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1209990", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008091156", 
          "https://doi.org/10.1038/sj.onc.1209990"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1209990", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008091156", 
          "https://doi.org/10.1038/sj.onc.1209990"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bbrc.2005.03.166", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017102714"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.274.14.9351", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025560502"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.18.9514", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027093675"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-0736-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027724077"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-04-1655", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031995280"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1207902", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032812682", 
          "https://doi.org/10.1038/sj.onc.1207902"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1207902", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032812682", 
          "https://doi.org/10.1038/sj.onc.1207902"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0197-2456(94)90004-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038163610"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0197-2456(94)90004-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038163610"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1167/iovs.09-3617", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039803253"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.23810", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043582157"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-07-6720", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044217275"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.14.5482", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044922442"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdf274", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052882288"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077005576", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.26.15_suppl.8051", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079372639"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.6.2403", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083106816"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-12", 
    "datePublishedReg": "2010-12-01", 
    "description": "BACKGROUND: The phosphoinositide 3-kinase (PI3K)/Akt pathway is constitutively activated in pancreatic cancer and the mammalian target of rapamycin (mTOR) kinase is an important mediator for its signaling. Our recent in vitro studies suggest that prolonged exposure of pancreatic cancer cells to mTOR inhibitors can promote insulin receptor substrate-PI3K interactions and paradoxically increase Akt phosphorylation and cyclin D1 expression in pancreatic cancer cells (negative feedback loop). The addition of erlotinib to rapamycin can down-regulate rapamycin-stimulated Akt and results in synergistic antitumor activity with erlotinib in preclinical tumor models.\nMETHODS: Two studies prospectively enrolled adult patients with advanced pancreatic cancer, Eastern Cooperative Oncology Group performance status 0-1, adequate hematologic, hepatic and renal parameters and measurable disease. In Study A, temsirolimus was administered intravenously at 25 mg weekly. In Study B, everolimus was administered orally at 30 mg weekly and erlotinib was administered at 150 mg daily. The primary endpoint in both studies was overall survival at 6 months. Secondary endpoints included time to progression, progression-free survival, overall survival, response rate, safety and toxicity. Pretreatment tumor biopsies were analyzed by immunofluorescence and laser scanning cytometry for the expression of pmTOR/mTOR, pAkt/Akt, pErk/Erk, pS6, p4EBP-1 and PTEN.\nRESULTS: Five patients enrolled in Study A; Two patients died within a month (rapid disease progression and hemorrhagic stroke, respectively). One patient developed dehydration and another developed asthenia. Sixteen patients enrolled in Study B.: 12 males, all ECOG PS = 1. Median cycles = 1 (range 1-2). Grade 4 toxicity: hyponatremia (n = 1), Grade 3: diarrhea (n = 1), cholangitis (n = 3), hyperglycemia (n = 1), fatigue (n = 1). Grade 2: pneumonia (n = 2), dehydration (n = 2), nausea (n = 2), neutropenia (n = 1), mucositis (n = 2) & rash (n = 2). Four patients were hospitalized. Progressive disease occurred in 15 and 1 was non-evaluable. Pretreatment biopsies revealed a higher pAkt/Akt ratio in tumor specimens that in nonmalignant pancreatic tissue. No such trends were noted for the other biomarkers.\nCONCLUSIONS: Neither study with mTOR inhibitors demonstrated objective responses or disease stability. The negative feedback loop resulting from mTOR inhibition may account for the disease progression and toxicity noted in these studies. Future strategies should aim for a broader targeting of the PI3K pathway in pancreatic cancer.\nTRIAL REGISTRATION: \nTRIAL REGISTRATION: \nSTUDY A: NCT 0075647.\nSTUDY B: NCT00640978.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1471-2407-10-368", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "name": "Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies", 
    "pagination": "368", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "281ab38f4cfcaf81d5778fb8e311a66c20bc75ac9be297f2bf7040ca8b32950e"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20630061"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1471-2407-10-368"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1008418244"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1471-2407-10-368", 
      "https://app.dimensions.ai/details/publication/pub.1008418244"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T16:41", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8669_00000510.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1471-2407-10-368"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-10-368'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-10-368'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-10-368'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-10-368'


 

This table displays all metadata directly associated to this object as RDF triples.

306 TRIPLES      21 PREDICATES      76 URIs      48 LITERALS      36 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1471-2407-10-368 schema:about N013136cac95f4fb294322f96629e55d1
2 N08ccb1dc56264f1b930caf45218eef30
3 N0c5d3925d28d40d18668f4846135ede0
4 N13d24eb508394a5dafd54fb5177c33eb
5 N220eaece295348bbb0d466ba96d60fa6
6 N25530d8e7c9a41edb83fe9f8c4873346
7 N34f263518c17458dbaf9a9614bb49d2a
8 N42dc247963c6469caa2c9004451d7c7f
9 N4519610bdea8405d9b90a2499445d594
10 N4713c143a11047edaec8a9ea36fa0e4a
11 N56efc180067f4f13a17aa025819718d3
12 N5888c37f3daa457e8fc99e0c3433083a
13 N61485b7ce2e14d96ba120eb5ae192001
14 N689561205c10465db1ff70af0a2f82ec
15 N69c53112c4214bfc8ded31bb82dec518
16 N9200959f27944d1fa66f8f46d5c4c5eb
17 N99f2e54ffb844287addc50d44d6ecbc1
18 Nc2d24dd6db724b0d932164f230d49ef2
19 Nc7406ebb5d234d958b549ef1f8283c48
20 Nc94a3f606ddd4cd0818fe0d3ac77bb2b
21 Nd20cd4665c644ed5bba3ea97eaf33854
22 Nd981487001bb4560a61251f16e6a10dc
23 Ne01518e4e99a460ea5162a3442467ab7
24 Ne0e881b790e54a4497666dfceca74d35
25 Ne8710a35e81c4d7aadf1faae3be8cafb
26 Ne97eaae024bd41c4b3981f991076763d
27 Nf87ec857ba0d4adf8b2b609c99997fc4
28 anzsrc-for:11
29 anzsrc-for:1112
30 schema:author N7105c53cfbc54e719fa937be504a8d95
31 schema:citation sg:pub.10.1038/sj.onc.1207902
32 sg:pub.10.1038/sj.onc.1209990
33 https://app.dimensions.ai/details/publication/pub.1077005576
34 https://doi.org/10.1002/cncr.23810
35 https://doi.org/10.1016/0197-2456(94)90004-3
36 https://doi.org/10.1016/j.bbrc.2005.03.166
37 https://doi.org/10.1016/j.ejca.2008.10.026
38 https://doi.org/10.1074/jbc.274.14.9351
39 https://doi.org/10.1093/annonc/mdf274
40 https://doi.org/10.1097/01.cco.0000143964.74936.d1
41 https://doi.org/10.1158/0008-5472.can-07-6720
42 https://doi.org/10.1158/1078-0432.ccr-04-1655
43 https://doi.org/10.1158/1078-0432.ccr-0736-3
44 https://doi.org/10.1158/1535-7163.mct-06-0166
45 https://doi.org/10.1167/iovs.09-3617
46 https://doi.org/10.1200/jco.1997.15.6.2403
47 https://doi.org/10.1200/jco.2006.07.9525
48 https://doi.org/10.1200/jco.2007.14.5482
49 https://doi.org/10.1200/jco.2008.18.9514
50 https://doi.org/10.1200/jco.2008.26.15_suppl.8051
51 schema:datePublished 2010-12
52 schema:datePublishedReg 2010-12-01
53 schema:description BACKGROUND: The phosphoinositide 3-kinase (PI3K)/Akt pathway is constitutively activated in pancreatic cancer and the mammalian target of rapamycin (mTOR) kinase is an important mediator for its signaling. Our recent in vitro studies suggest that prolonged exposure of pancreatic cancer cells to mTOR inhibitors can promote insulin receptor substrate-PI3K interactions and paradoxically increase Akt phosphorylation and cyclin D1 expression in pancreatic cancer cells (negative feedback loop). The addition of erlotinib to rapamycin can down-regulate rapamycin-stimulated Akt and results in synergistic antitumor activity with erlotinib in preclinical tumor models. METHODS: Two studies prospectively enrolled adult patients with advanced pancreatic cancer, Eastern Cooperative Oncology Group performance status 0-1, adequate hematologic, hepatic and renal parameters and measurable disease. In Study A, temsirolimus was administered intravenously at 25 mg weekly. In Study B, everolimus was administered orally at 30 mg weekly and erlotinib was administered at 150 mg daily. The primary endpoint in both studies was overall survival at 6 months. Secondary endpoints included time to progression, progression-free survival, overall survival, response rate, safety and toxicity. Pretreatment tumor biopsies were analyzed by immunofluorescence and laser scanning cytometry for the expression of pmTOR/mTOR, pAkt/Akt, pErk/Erk, pS6, p4EBP-1 and PTEN. RESULTS: Five patients enrolled in Study A; Two patients died within a month (rapid disease progression and hemorrhagic stroke, respectively). One patient developed dehydration and another developed asthenia. Sixteen patients enrolled in Study B.: 12 males, all ECOG PS = 1. Median cycles = 1 (range 1-2). Grade 4 toxicity: hyponatremia (n = 1), Grade 3: diarrhea (n = 1), cholangitis (n = 3), hyperglycemia (n = 1), fatigue (n = 1). Grade 2: pneumonia (n = 2), dehydration (n = 2), nausea (n = 2), neutropenia (n = 1), mucositis (n = 2) & rash (n = 2). Four patients were hospitalized. Progressive disease occurred in 15 and 1 was non-evaluable. Pretreatment biopsies revealed a higher pAkt/Akt ratio in tumor specimens that in nonmalignant pancreatic tissue. No such trends were noted for the other biomarkers. CONCLUSIONS: Neither study with mTOR inhibitors demonstrated objective responses or disease stability. The negative feedback loop resulting from mTOR inhibition may account for the disease progression and toxicity noted in these studies. Future strategies should aim for a broader targeting of the PI3K pathway in pancreatic cancer. TRIAL REGISTRATION: TRIAL REGISTRATION: STUDY A: NCT 0075647. STUDY B: NCT00640978.
54 schema:genre research_article
55 schema:inLanguage en
56 schema:isAccessibleForFree true
57 schema:isPartOf N2432927869724cdfab06c8af47894d4d
58 N9f628fecdc284144941c2083eece58e2
59 sg:journal.1024632
60 schema:name Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
61 schema:pagination 368
62 schema:productId N035ee5486f924d028c3ebe2ff4fe5e44
63 N303b5bc2b1914d4f863814b343ba08f4
64 N7b3bff9962d545cd9ad32d9aaf9588d4
65 Nb0e0efff54004e7d82a07a29fe63703d
66 Nba9c82991482432a89943542cb90085c
67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008418244
68 https://doi.org/10.1186/1471-2407-10-368
69 schema:sdDatePublished 2019-04-10T16:41
70 schema:sdLicense https://scigraph.springernature.com/explorer/license/
71 schema:sdPublisher N9481a03baf7746f88ffd8786de68f3ae
72 schema:url http://link.springer.com/10.1186%2F1471-2407-10-368
73 sgo:license sg:explorer/license/
74 sgo:sdDataset articles
75 rdf:type schema:ScholarlyArticle
76 N013136cac95f4fb294322f96629e55d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Aged
78 rdf:type schema:DefinedTerm
79 N035ee5486f924d028c3ebe2ff4fe5e44 schema:name nlm_unique_id
80 schema:value 100967800
81 rdf:type schema:PropertyValue
82 N0480ebacd926497bb064572e22a7a29e rdf:first sg:person.01133335751.97
83 rdf:rest N149454f83e43439e805859f0173121fe
84 N08ccb1dc56264f1b930caf45218eef30 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Humans
86 rdf:type schema:DefinedTerm
87 N0c5d3925d28d40d18668f4846135ede0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name TOR Serine-Threonine Kinases
89 rdf:type schema:DefinedTerm
90 N13d24eb508394a5dafd54fb5177c33eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Prognosis
92 rdf:type schema:DefinedTerm
93 N149454f83e43439e805859f0173121fe rdf:first sg:person.0645263515.62
94 rdf:rest rdf:nil
95 N1c1fea3af6c04b3db35cbe5ddaccd824 rdf:first sg:person.012547340642.09
96 rdf:rest Nfbce6e04496f4d95893273ff220556bf
97 N220eaece295348bbb0d466ba96d60fa6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Quinazolines
99 rdf:type schema:DefinedTerm
100 N2432927869724cdfab06c8af47894d4d schema:issueNumber 1
101 rdf:type schema:PublicationIssue
102 N25530d8e7c9a41edb83fe9f8c4873346 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Erlotinib Hydrochloride
104 rdf:type schema:DefinedTerm
105 N303b5bc2b1914d4f863814b343ba08f4 schema:name readcube_id
106 schema:value 281ab38f4cfcaf81d5778fb8e311a66c20bc75ac9be297f2bf7040ca8b32950e
107 rdf:type schema:PropertyValue
108 N34f263518c17458dbaf9a9614bb49d2a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Proto-Oncogene Proteins c-akt
110 rdf:type schema:DefinedTerm
111 N42dc247963c6469caa2c9004451d7c7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Immunoenzyme Techniques
113 rdf:type schema:DefinedTerm
114 N4519610bdea8405d9b90a2499445d594 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Middle Aged
116 rdf:type schema:DefinedTerm
117 N4713c143a11047edaec8a9ea36fa0e4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Antineoplastic Combined Chemotherapy Protocols
119 rdf:type schema:DefinedTerm
120 N56efc180067f4f13a17aa025819718d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Everolimus
122 rdf:type schema:DefinedTerm
123 N5888c37f3daa457e8fc99e0c3433083a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Adenocarcinoma
125 rdf:type schema:DefinedTerm
126 N5bcb870b78ff43bfa2faf84e9f64a786 rdf:first sg:person.01120712765.07
127 rdf:rest Nf82108c9b7714480b675056c41593056
128 N61485b7ce2e14d96ba120eb5ae192001 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Protein Kinase Inhibitors
130 rdf:type schema:DefinedTerm
131 N689561205c10465db1ff70af0a2f82ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Male
133 rdf:type schema:DefinedTerm
134 N69c53112c4214bfc8ded31bb82dec518 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Phosphorylation
136 rdf:type schema:DefinedTerm
137 N7105c53cfbc54e719fa937be504a8d95 rdf:first sg:person.01170552013.73
138 rdf:rest N5bcb870b78ff43bfa2faf84e9f64a786
139 N7b3bff9962d545cd9ad32d9aaf9588d4 schema:name pubmed_id
140 schema:value 20630061
141 rdf:type schema:PropertyValue
142 N7f0a8a0e50524b39a7083170c8488bbd schema:name Apocell Inc, 2575 West Bellfort, Suite 190, Houston, TX, USA
143 rdf:type schema:Organization
144 N9200959f27944d1fa66f8f46d5c4c5eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Fluorescent Antibody Technique
146 rdf:type schema:DefinedTerm
147 N9481a03baf7746f88ffd8786de68f3ae schema:name Springer Nature - SN SciGraph project
148 rdf:type schema:Organization
149 N99f2e54ffb844287addc50d44d6ecbc1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Prospective Studies
151 rdf:type schema:DefinedTerm
152 N9f628fecdc284144941c2083eece58e2 schema:volumeNumber 10
153 rdf:type schema:PublicationVolume
154 Na4b523fc35104c239e529f81d7d78598 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
155 schema:familyName Varadhachary
156 schema:givenName Gauri A
157 rdf:type schema:Person
158 Nb0e0efff54004e7d82a07a29fe63703d schema:name dimensions_id
159 schema:value pub.1008418244
160 rdf:type schema:PropertyValue
161 Nba9c82991482432a89943542cb90085c schema:name doi
162 schema:value 10.1186/1471-2407-10-368
163 rdf:type schema:PropertyValue
164 Nc2d24dd6db724b0d932164f230d49ef2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Pancreatic Neoplasms
166 rdf:type schema:DefinedTerm
167 Nc6f6db62d1004ebeb2db2f2205421736 rdf:first Na4b523fc35104c239e529f81d7d78598
168 rdf:rest Ne65a396a7f6f4b60b633edec82c4df36
169 Nc7406ebb5d234d958b549ef1f8283c48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Receptor, Epidermal Growth Factor
171 rdf:type schema:DefinedTerm
172 Nc94a3f606ddd4cd0818fe0d3ac77bb2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Adult
174 rdf:type schema:DefinedTerm
175 Nd20cd4665c644ed5bba3ea97eaf33854 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Neoplasm Staging
177 rdf:type schema:DefinedTerm
178 Nd981487001bb4560a61251f16e6a10dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Survival Rate
180 rdf:type schema:DefinedTerm
181 Ne01518e4e99a460ea5162a3442467ab7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Signal Transduction
183 rdf:type schema:DefinedTerm
184 Ne0e881b790e54a4497666dfceca74d35 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Immunosuppressive Agents
186 rdf:type schema:DefinedTerm
187 Ne65a396a7f6f4b60b633edec82c4df36 rdf:first sg:person.01137701711.27
188 rdf:rest N1c1fea3af6c04b3db35cbe5ddaccd824
189 Ne8710a35e81c4d7aadf1faae3be8cafb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Biomarkers, Tumor
191 rdf:type schema:DefinedTerm
192 Ne97eaae024bd41c4b3981f991076763d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Sirolimus
194 rdf:type schema:DefinedTerm
195 Nf2e15da712d54d84acd933f868bf3304 rdf:first sg:person.01240504261.54
196 rdf:rest N0480ebacd926497bb064572e22a7a29e
197 Nf82108c9b7714480b675056c41593056 rdf:first sg:person.016444546257.55
198 rdf:rest Nc6f6db62d1004ebeb2db2f2205421736
199 Nf87ec857ba0d4adf8b2b609c99997fc4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Female
201 rdf:type schema:DefinedTerm
202 Nfbb63d394f2247a4b1ce0e5c6e5c7c42 schema:name Apocell Inc, 2575 West Bellfort, Suite 190, Houston, TX, USA
203 rdf:type schema:Organization
204 Nfbce6e04496f4d95893273ff220556bf rdf:first sg:person.01143530612.06
205 rdf:rest Nf2e15da712d54d84acd933f868bf3304
206 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
207 schema:name Medical and Health Sciences
208 rdf:type schema:DefinedTerm
209 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
210 schema:name Oncology and Carcinogenesis
211 rdf:type schema:DefinedTerm
212 sg:journal.1024632 schema:issn 1471-2407
213 schema:name BMC Cancer
214 rdf:type schema:Periodical
215 sg:person.01120712765.07 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
216 schema:familyName Shroff
217 schema:givenName Rachna T
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01120712765.07
219 rdf:type schema:Person
220 sg:person.01133335751.97 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
221 schema:familyName Wolff
222 schema:givenName Robert A
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133335751.97
224 rdf:type schema:Person
225 sg:person.01137701711.27 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
226 schema:familyName Fogelman
227 schema:givenName David
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137701711.27
229 rdf:type schema:Person
230 sg:person.01143530612.06 schema:affiliation Nfbb63d394f2247a4b1ce0e5c6e5c7c42
231 schema:familyName Davis
232 schema:givenName Darren
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01143530612.06
234 rdf:type schema:Person
235 sg:person.01170552013.73 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
236 schema:familyName Javle
237 schema:givenName Milind M
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170552013.73
239 rdf:type schema:Person
240 sg:person.01240504261.54 schema:affiliation N7f0a8a0e50524b39a7083170c8488bbd
241 schema:familyName Zhang
242 schema:givenName Yujian
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240504261.54
244 rdf:type schema:Person
245 sg:person.012547340642.09 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
246 schema:familyName Reddy
247 schema:givenName Shrikanth A
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012547340642.09
249 rdf:type schema:Person
250 sg:person.016444546257.55 schema:affiliation https://www.grid.ac/institutes/grid.477919.5
251 schema:familyName Xiong
252 schema:givenName Henry
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016444546257.55
254 rdf:type schema:Person
255 sg:person.0645263515.62 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
256 schema:familyName Abbruzzese
257 schema:givenName James L
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645263515.62
259 rdf:type schema:Person
260 sg:pub.10.1038/sj.onc.1207902 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032812682
261 https://doi.org/10.1038/sj.onc.1207902
262 rdf:type schema:CreativeWork
263 sg:pub.10.1038/sj.onc.1209990 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008091156
264 https://doi.org/10.1038/sj.onc.1209990
265 rdf:type schema:CreativeWork
266 https://app.dimensions.ai/details/publication/pub.1077005576 schema:CreativeWork
267 https://doi.org/10.1002/cncr.23810 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043582157
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1016/0197-2456(94)90004-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038163610
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1016/j.bbrc.2005.03.166 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017102714
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1074/jbc.274.14.9351 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025560502
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1093/annonc/mdf274 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052882288
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1097/01.cco.0000143964.74936.d1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003424823
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1158/0008-5472.can-07-6720 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044217275
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1158/1078-0432.ccr-04-1655 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031995280
284 rdf:type schema:CreativeWork
285 https://doi.org/10.1158/1078-0432.ccr-0736-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027724077
286 rdf:type schema:CreativeWork
287 https://doi.org/10.1158/1535-7163.mct-06-0166 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004420604
288 rdf:type schema:CreativeWork
289 https://doi.org/10.1167/iovs.09-3617 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039803253
290 rdf:type schema:CreativeWork
291 https://doi.org/10.1200/jco.1997.15.6.2403 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083106816
292 rdf:type schema:CreativeWork
293 https://doi.org/10.1200/jco.2006.07.9525 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005176755
294 rdf:type schema:CreativeWork
295 https://doi.org/10.1200/jco.2007.14.5482 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044922442
296 rdf:type schema:CreativeWork
297 https://doi.org/10.1200/jco.2008.18.9514 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027093675
298 rdf:type schema:CreativeWork
299 https://doi.org/10.1200/jco.2008.26.15_suppl.8051 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079372639
300 rdf:type schema:CreativeWork
301 https://www.grid.ac/institutes/grid.240145.6 schema:alternateName The University of Texas MD Anderson Cancer Center
302 schema:name Department of Gastrointestinal Medical Oncology, UT-M D Anderson Cancer Center, Houston, TX, USA
303 rdf:type schema:Organization
304 https://www.grid.ac/institutes/grid.477919.5 schema:alternateName Center for Cancer and Blood Disorders
305 schema:name Center for Cancer and Blood Disorders, Dallas, TX, USA
306 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...